At present, clinical therapy with PARP inhibitors is far from being achieved; however, a shorter-term indirect approach may involve the α-lipoic acid, which has been demonstrated to inhibit diabetes-induced PARP overactivation in preclinical studies [21,211]. This evidence concerns the gene PARP1 and diabetes mellitus.